Latest news and research on all cancers and treatments, updated several times a week, plus 10,000-item data base of these
When cancer strikes, it may be possible for patients to fight back with their own defenses, using a strategy known as immunotherapy. According to a ...
Cancer immunotherapy has been in the spotlight since quite some time now. Several companies are looking to bring immuno-oncology drugs to ...
Cancer research at UCLA's Jonsson Comprehensive Cancer Center ... to boost immunotherapy; in addition, it reduced the likelihood of the cancer ...
Dr. Carl June leads the team responsible for a promising trial in which the body's immune system is turned into a cancer-fighting weapon. He and a ...
The Ben May Department for Cancer Research at the University of Chicago will ... Immunotherapies enable the body's immune system to fight tumors.
The American Cancer Society says that obesity may interfere with immune systemfunctions, or affect levels of hormones, such as estrogen and insulin ...
NEW YORK — Can a tetanus shot help treat brain cancer? ... effort to harness the immune system to fight cancer, an approach called immunotherapy.
In cancer, macrophages suppress the immune system's ability to kill cancer cells. In joint diseases, such as PVNS and RA, macrophages play a central ...
... to play a key role in suppressing the immune system by hindering the proliferation of CD8+ T cells, the body's front-line attackers of foreign antigens.
The patient was treated at the Dana-Farber Cancer Institute in Boston, MA ... by harnessing the human immune system to target and kill the cancer.
Pancreatic cancer: A reduced risk of pancreatic cancer was seen in men who drank at least three cups of coffee per day. This effect was not seen in ...
... MPDL3280A enjoys breakthrough therapy designation in the U.S. for both non-small cell lung cancer (NSCLC) and metastatic bladder cancer.
Indeed, retrospective genome sequencing of 14 bladder cancer patients from a phase II study evaluating the efficiency of everolimus revealed that ...
A science paper describing the clinical performance of its bladder cancer test Cxbladder Triage has also been accepted by the medical journal ...
Immunotherapy with Bacillus Calmette-Guérin (BCG) is the most efficacious treatment for high-risk bladder cancer (BC) (Ta/T1 or carcinoma in situ) to ...
Increased Colorectal Cancer Screening May Decrease Incidence, Mortality
If US colorectal cancer screening is increased to 80% by 2018, a new study predicts a decrease in both cancer incidence and mortality within 20 years.
If US colorectal cancer screening is increased to 80% by 2018, a new study predicts a decrease in both cancer incidence and mortality within 20 years.
Breast Cancer Risk Connected to Family History of Prostate Cancer
Women with a first-degree relative diagnosed with prostate cancer may be at increased risk for developing breast cancer, according to a new study.
Women with a first-degree relative diagnosed with prostate cancer may be at increased risk for developing breast cancer, according to a new study.
Early-Onset Alopecia May Signal Chemotherapy Response for Ovarian Cancer
Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.
Onset of alopecia within the first 3 cycles of chemotherapy was associated with improved survival in ovarian cancer patients who completed 6 cycles of chemo.
Testosterone Levels During ADT May Predict Prostate Cancer Outcomes
A reduction in testosterone levels in the first year of ADT correlates with improved survival in prostate cancer patients being treated for biochemical failure.
A reduction in testosterone levels in the first year of ADT correlates with improved survival in prostate cancer patients being treated for biochemical failure.
Fracture Risk Increased After Hematopoietic Stem-Cell Transplantation
Results of a single-institution study found the risk for fracture among survivors of hematopoietic stem-cell transplantation increased by nearly eight times.
Results of a single-institution study found the risk for fracture among survivors of hematopoietic stem-cell transplantation increased by nearly eight times.
Novel Imatinib/Nilotinib Strategy Could Optimize CML Treatment
A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.
A single-arm, open-label trial in Australia found that selective early switching from imatinib to nilotinib is feasible and effective in patients with CML.
Angiogenic Factors Linked to Esophageal Cancer Outcomes
A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.
A retrospective analysis found that high expression levels of two angiogenic factors were associated with poor prognosis in esophageal cancer.
Second-Gen TKIs Better in CML Patients With Elevated CIP2A Levels
CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.
CML patients with high CIP2A levels treated with second-generation tyrosine kinase inhibitors have better outcomes than those treated with imatinib.
TP53 Mutations in Early-Onset CRC Not Linked With Li-Fraumeni Syndrome
Looking at a large group of early-onset colorectal cancer patients, only 1.3% had TP53 mutations, none of whom met criteria for Li-Fraumeni syndrome.
Looking at a large group of early-onset colorectal cancer patients, only 1.3% had TP53 mutations, none of whom met criteria for Li-Fraumeni syndrome.
Possible Target Found in ARID1A-Mutated Ovarian Cancers
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
Researchers have discovered that ovarian cancers with ARID1A mutations may be sensitive to treatment with an inhibitor of EZH2 methyltransferase activity.
ENDEAVOR: Carfilzomib Doubles PFS in Relapsed Myeloma
Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.
Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.
Inflammatory Marker Linked With Poor Prognosis in Melanoma
The measurement of levels of C-reactive protein (CRP) in the blood has been found to be an independent prognostic marker for survival in patients with melanoma.
The measurement of levels of C-reactive protein (CRP) in the blood has been found to be an independent prognostic marker for survival in patients with melanoma.
Science Daily Cancer News
Modern life, with its preponderance of inadequate exposure to natural light during the day and overexposure to artificial light at night, is not conducive to the body's natural sleep/wake cycle. A cancer epidemiologist and team members suggest such overexposure has possible ties to cancer, obesity, diabetes, and other health issues.
A ground-breaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects.
The molecular mechanism of cancer development caused by well-known 'resistance' mutations in the gene called epidermal growth factor receptor has been revealed by researchers for the first time. While these mutations were known for quite a long time, the question as to why they cause cancer or make some drugs ineffective was still not answered.
Green tea's popularity has grown quickly in recent years. Its fans can drink it, enjoy its flavor in their ice cream and slather it on their skin with lotions infused with it. Now, the tea could have a new, unexpected role -- to improve the image quality of MRIs. Scientists report that they successfully used compounds from green tea to help image cancer tumors in mice.
Conclusive results have been revealed in reducing toxicities for Asian patients with metastatic renal cell carcinoma or cancer that has spread beyond the kidney. The findings have revolutionized the standard protocol for patient management in NCCS with an attenuated-dose regimen of sunitinib for patients with mRCC.
Regarding lung cancer, the early repeat scan rate for suspicious findings decreased by more than 80 percent with the second and subsequent low-dose computed tomography screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison, a study shows.
A mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells has been found by researchers. The findings, which are at odds with a 2013 study asserting that omega-3s increase the risk of prostate cancer, point the way to more effective anti-cancer drugs.
A new study is assessing patients with metastasized bowel cancer to determine whether it is possible to characterize tumor and better control resistance mechanisms with a blood test. The aim of this is to spare patients the stress of having tissue removed via biopsies and to make the targeted use of therapy easier.
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
Tambahkan Komentar